A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Inclusion Criteria: * Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb * Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months * Patients below the age of 75 Exclusion Criteria: * Patients with valvular heart disease/congenital heart disease * Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery * Patients with history of heart failure * Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months * Patients with thalassemic trait or haemoglobinopathies * Patients with underlying haematological malignancies * Patients with active bleeding * Patients with uncorrected iron or other vitamins deficiencies * Patients with poor general condition